Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer.
Salvatore Paiella, Gabriele Capurso, Silvia Carrara...
https://pubmed.ncbi.nlm.nih.gov/37787643/Actively Recruiting
Led by Associazione Italiana per lo Studio del Pancreas · Updated on 2023-01-13
1000
Participants Needed
4
Research Sites
56 weeks
Total Duration
Researchers are studying individuals who have an inherited increased risk of pancreatic cancer through a national multicenter registry called IRFARPC. The study focuses on understanding the diagnosis and factors that predispose people to pancreatic cancer, which is known for its poor prognosis. Early detection through screening and surveillance is explored as a possible way to improve outcomes, especially in people with family history or genetic conditions linked to the disease. Participants include adults over 18 years old with specific genetic mutations or syndromes such as BRCA12, PALB2, p16 mutations, Peutz-Jeghers syndrome, FAMMM syndrome, Lynch syndrome with family history of pancreatic cancer, hereditary pancreatitis, or familial pancreatic cancer. Those who meet age-based criteria may enter a surveillance program involving imaging tests like Cholangio-Wirsung Magnetic Resonance MRCP or Pancreatic Endoultrasonography EUS as recommended by pancreatologists at participating centers. During the study, researchers collect family history, genetic information, medical records, and medication data. Participants undergoing surveillance receive imaging exams to detect pancreatic neoplasia or precancerous lesions. The study will evaluate the effectiveness of this surveillance over 25 years, looking at diagnostic yield and risk factors for pancreatic neoplasia progression. The overall participation may last up to 25 years, with ongoing monitoring and data collection.
CONDITIONS
Registry of Subjects at Risk of Pancreatic Cancer
S
Salvatore Paiella, MD, PhD
S
Silvia Carrara, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Associazione Italiana per lo Studio del Pancreas
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 25 years
Participants at risk of pancreatic cancer are monitored through imaging procedures such as Cholangio-Wirsung Magnetic Resonance or Pancreatic Endoultrasonography based on their pancreatologist's prescription.
Visits scheduled according to pancreatologist's prescription
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Have more questions? Get in touch with our team for quick support
Salvatore Paiella, Gabriele Capurso, Silvia Carrara...
https://pubmed.ncbi.nlm.nih.gov/37787643/Salvatore Paiella, Gabriele Capurso, Giulia Martina Cavestro...
https://pubmed.ncbi.nlm.nih.gov/30538291/Associazione Italiana per lo Studio del Pancreas
Lead Sponsor